Anti-Reflux Devices Market Size, Share, and COVID-19 Impact Analysis | Global | 2022-2028

The global anti-reflux device market was valued at nearly $199 million in 2025. The market is projected to grow at a compound annual growth rate of 16.2 percent, reaching over $567 million by 2032.

This report covers procedure-based device approaches for gastroesophageal reflux disease (GERD), including transoral incisionless fundoplication (TIF), transesophageal radiofrequency therapy, and the LINX Reflux Management System. It quantifies unit sales, average selling prices (ASPs), market values, growth rates, and company shares, and it analyzes market drivers and limiters, recent mergers and acquisitions, and technology trends. It provides historical data to 2022 and forecasts to 2032.

The scope reflects how providers evaluate device-based GERD interventions relative to drug therapy and laparoscopic surgery across hospitals and specialty centers, as awareness rises, evidence grows, and patient preferences shift toward durable symptom relief with predictable recovery.

Market Overview

Anti-reflux devices address persistent GERD by reinforcing the barrier function at the gastroesophageal junction or by remodeling the lower esophageal sphincter. These interventions offer an option for patients who seek alternatives to long-term proton-pump inhibitor therapy or who remain symptomatic despite medication.

Growth is supported by three converging forces. First, product awareness has improved through targeted physician education and patient marketing by leading manufacturers. As more centers adopt TIF, radiofrequency therapy, and magnetic augmentation, procedural familiarity grows and referral pathways mature. Second, concerns about long-term PPI use have increased. Studies linking extended PPI therapy to hypomagnesemia and fracture risk have prompted many patients and physicians to reassess long-term medication plans. Third, obesity prevalence continues to rise, and central adiposity is associated with higher GERD symptom burden and reduced control with lifestyle changes alone. Together these forces support a steady increase in consultations for device-based therapy and a larger addressable market.

Adoption patterns vary by setting. Academic hospitals and high-volume GI centers often build structured reflux programs that include pre-procedure diagnostics, standardized patient selection, and coordinated follow-up. Community facilities tend to scale more gradually, focusing on one or two techniques that fit local skills and patient demand. Across settings, patient selection remains central. Clinicians weigh symptom severity, anatomy, hiatal hernia presence and size, motility status, and medication response to direct patients to the most suitable option.

Price and value dynamics reflect a balance between up-front device cost and downstream benefits. Providers emphasize procedural success rates, durability of symptom relief, reintervention rates, and the ability to reduce daily medication use. Payors and integrated systems focus on total cost of care, length of stay, and complication avoidance. As evidence accumulates and coding clarity improves, the market signals continued expansion from 2025 through 2032.

Market Drivers

Increased product awareness

Sustained marketing and education by leading companies have raised recognition of anti-reflux devices among surgeons, gastroenterologists, and patients. Peer-reviewed publications, conference workshops, and proctorship programs have improved visibility and confidence. As awareness rises, more candidates who are dissatisfied with long-term medication or who prefer a procedural solution are entering care pathways that include TIF, radiofrequency therapy, or magnetic augmentation. Surgeon familiarity increases procedure readiness and reduces perceived barriers to adoption.

Side effects of PPI medication

PPIs remain the first-line therapy for GERD, but concerns about long-term use are influencing treatment decisions. Extended exposure is associated with low serum magnesium levels, which can lead to irregular heartbeats, muscle spasms, and seizures. High-dose therapy is linked to increased risk of osteoporosis and fractures involving the wrist, spine, and hip. These safety signals do not eliminate the role of PPIs, but they prompt shared decision-making around duration and alternatives. As more patients seek durable symptom control without indefinite medication, device demand rises.

Increasing obesity

There is a well-documented relationship between central obesity and GERD symptom severity. As global obesity rates increase, the pool of patients with frequent reflux, nocturnal symptoms, and reduced medication response grows. Providers who already manage obesity-related comorbidities are expanding referral pathways to include device-based GERD treatments. As device credibility increases, a portion of this rising demand shifts from chronic medication toward procedural solutions, supporting total market growth.

Evidence and workflow maturation

Clinical protocols for patient selection, anesthesia, device sizing, and follow-up are improving. More centers standardize pre-procedure testing and use consistent patient-reported outcome measures. This leads to better case selection, more predictable results, and stronger satisfaction scores. As workflows stabilize, facilities are more willing to invest in staff training and capital support, which accelerates adoption.

Market Limiters

Pharmaceutical competition

Despite growing concerns, PPIs remain accessible and effective for many patients. Generics lower out-of-pocket costs and maintain adherence. New formulations and dosing strategies can reduce breakthrough symptoms, which delays or replaces referral for device therapy. If novel medications improve response in non-responders, device adoption may be tempered, especially in cost-sensitive markets where payors require medication optimization before authorizing a procedure.

Patient discomfort and expectations

All implant and energy-based procedures carry surgical risks and recovery considerations. Some patients report dysphagia, bloating, and chest discomfort after implantation or energy delivery. Difficulty swallowing and diet adjustments can affect early satisfaction. In a minority of cases, device removal occurs. The possibility of symptom persistence and the prospect of continuing daily medication even after a procedure can also reduce interest among patients who expect complete independence from drugs.

Follow-up medication usage

A share of patients will still need daily acid suppression after device therapy, although at lower doses or less frequently. For value-focused payors and patients, this reduces the perceived gap between medication-only care and procedure plus medication. Managing expectations and aligning on realistic outcomes is essential. Where communication is inconsistent, conversion rates fall and word-of-mouth slows.

Coverage variation and procurement limits

Coding clarity and coverage policies vary by region. In markets where reimbursement pathways are fragmented, hospitals face administrative hurdles that discourage program investment. In addition, certain group purchasing or tender processes limit rapid introduction of new devices and constrain price realization, particularly outside the United States.

Market Coverage and Data Scope

Quantitative coverage

Market size, market shares, market forecasts, market growth rates, units sold, and average selling prices.

Qualitative coverage

Market growth trends and limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, FDA recalls, disruptive technologies, and disease overviews relevant to GERD.

Time frame

Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.

Data sources

Primary interviews with industry leaders and physicians, government physician data, regulatory data, hospital private data, import and export data, and the iData Research internal database.

Method note

Revenue is modeled from units multiplied by ASP, validated with procedure volumes, device utilization rates, and replacement or removal assumptions for each procedural category.

Care settings

Hospitals, specialty centers, and select ambulatory facilities with advanced endoscopy or foregut surgery capabilities.

Competitive Analysis

Johnson & Johnson

Johnson & Johnson offers the LINX Reflux Management System, a flexible ring of interlinked titanium beads with magnetic cores placed around the lower esophagus. The magnetic attraction resists reflux while allowing the beads to separate during swallowing. LINX appeals to patients seeking a mechanical solution that preserves normal anatomy. Its brand recognition, clinical track record, and clear mechanism of action support steady uptake in qualified candidates. The company's scale in surgical distribution and training strengthens its competitive position.

EndoGastric Solutions

EndoGastric Solutions is the second-leading competitor with the EsophyX system used for transoral incisionless fundoplication. The company has expanded market share through focused U.S. programs, patient outreach, and surgeon training. Growth is tied to broader adoption of incisionless approaches in centers that favor less invasive options with short recovery. Its presence outside the United States is growing through partnerships and training networks, but the company remains most active in the U.S. market.

Restech

Restech ranked third in 2025. The company acquired Mederi Therapeutics in 2018, which had previously acquired the Curon Medical assets and Stretta radiofrequency technology. Stretta delivers radiofrequency energy to remodel the lower esophageal sphincter and gastric cardia. Restech has increased share in Europe and other geographies by positioning Stretta as a minimally invasive alternative that can be performed without implants. Continued publication of outcomes data and disciplined training support gradual expansion.

Overall, the competitive field remains concentrated among a few specialized vendors with strong clinical messaging and structured training. Success depends on evidence generation, referral development, and consistent peri-procedural care to deliver durable outcomes.

Technology and Practice Trends

Procedure matching to patient phenotype is more common. Providers assess hernia size, esophagitis grade, motility, and BMI to align the device approach with anatomy and symptom pattern.

Standardized pre-procedure testing using pH monitoring, impedance, and manometry improves selection and supports payor documentation.

Peri-procedural pathways that include diet coaching, dysphagia management, and medication tapering improve satisfaction and reduce unplanned visits.

Durability tracking with structured follow-up and validated symptom scores builds confidence in long-term outcomes and publication quality.

Imaging and visualization advances in endoscopy and laparoscopy improve accuracy in device placement and troubleshooting.

Training and proctoring networks shorten the learning curve and expand the number of credentialed physicians who can perform these procedures safely.

Program economics emphasize case bundling, throughput, and inventory control, which helps centers justify investment and maintain predictable margins.

Geography

This edition provides global coverage for North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa

Methodology Appendix and Acronym Glossary

Why This Report

Where are the largest and fastest growing opportunities within anti-reflux devices and how will volumes evolve as awareness and coverage expand

How do PPI safety concerns and obesity trends translate into device referrals and long-term demand

What are the key barriers to adoption, including patient discomfort, continued medication use after procedures, and variable coverage policies

Which devices are best suited for specific patient profiles and how should centers structure reflux programs to improve throughput and outcomes

How do leading companies Johnson & Johnson, EndoGastric Solutions, and Restech position their portfolios and training to defend and expand share

What are the pricing and procurement dynamics that shape ASPs, from tenders to payor approvals, and how do facilities build a sustainable business case

The Global Anti-Reflux Device Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail. Use it to quantify demand, align portfolio strategy with patient selection pathways, and plan commercial execution that matches program economics and referral behavior.